PubMed Health⌕ Search

PubMed · 7812735

Dopamine does not mediate protein-induced hyperfiltration.

Abstract

Dopamine and a meat meal have both been used to stimulated hyperfiltration. Urinary dopamine has been said to rise after a meal. It has been suggested that the responses are the same. In order to clarify this relationship, the DOPA decarboxylase inhibitor carbidopa was used to abolish dopamine synthesis during a meat meal. Eight normal individuals were studied twice. On each occasion they ate a meat meal and resting and post-prandial haemodynamics were measured. On 1 of the 2 study days they received carbidopa which abolished renal dopamine synthesis. Despite this there was no change in resting haemodynamics and the meat meal response was preserved. We conclude that urinary dopamine does not rise after a meal and that dopamine does not mediate the meat meal response.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D M Thomas, G A Coles, J D Williams. Dopamine does not mediate protein-induced hyperfiltration.. https://pubmed.ncbi.nlm.nih.gov/7812735/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Dopamine agonist therapy for Parkinson disease and pathological gambling.

We report 6 patients with pathological gambling during pharmacologic treatment for Parkinson disease (PD). Four patients were treated with levodopa/carbidopa and dopamine agonist (DA), and 2 patients received DA monotherapy. We reviewed several published reports regarding pathological gambling and antiparkinsonian therapy and suggest that more advanced PD and antiparkinsonian combination therapy (e.g., levodopa/carbidopa and DA) increases the risk for development of pathological gambling behavior compared with monotherapy with either DA or levodopa/carbidopa.

Carbidopa↗

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.

Pharmacotherapy designed to alleviate the symptoms of Parkinson's disease is focused on the stimulation of striatal dopamine receptors. The ideal pharmacological treatment would involve continuous dopaminergic stimulation. Currently, the most effective pharmacotherapy available is levodopa delivered orally; however, its short plasma half-life in combination with erratic gastric emptying and intestinal absorption makes dopaminergic stimulation pulsatile. Motor fluctuations and dyskinesias develop with time as a consequence and can become disabling. A gel formulation of levodopa/carbidopa has been developed for enteral (duodenal or jejunal) infusion via a portable pump. The infusion provides smooth plasma levodopa levels, more continuous dopaminergic stimulation and effective treatment of motor complications.

Carbidopa↗